Boehringer Ingelheim GmbH presented Phase Ib results and Bayer AG reported Phase I/II data for their HER2 inhibitors at World Conference on Lung Cancer (WCLC) that showed greater response rates for their oral drugs in previously treated non-small cell lung cancer (NSCLC) with HER2 mutations than seen with the only approved therapy in this indication, the AstraZeneca PLC/Daiichi Sankyo Co., Ltd. HER2-directed ADC Enhertu (trastuzumab deruxtecan).
Boehringer, Bayer Kinase Inhibitors Offer Oral Option In HER2-Mutated Lung Cancer
Both Drugs In Phase III First-Line Trials
Boehringer presented Phase Ib results for zongertinib and Bayer presented Phase I/II results for BAY 2927088 in NSCLC with HER2 mutations – a rare cancer with ADC Enhertu as a major competitor – at the WCLC meeting.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.